China Pharma Holdings, Inc. (CPHI): Total Assets
$31.00M
As of 2025-12-31
$44.71M
As of 2026-06-30
+20.3%
3-year compound annual growth
+8.0%
5-year compound annual growth
-10.7%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $31.00M | +108.2% | 2026-04-01, Balance as of period end |
| 2024-12-31 | $14.89M | -9.6% | 2026-04-01, Balance as of period end |
| 2023-12-31 | $16.47M | -7.4% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $17.78M | -21.5% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $22.65M | +7.3% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $21.12M | -5.0% | 2022-03-30, Balance as of period end |
| 2019-12-31 | $22.24M | -51.0% | 2021-03-26, Balance as of period end |
| 2018-12-31 | $45.38M | -24.3% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $59.95M | -23.6% | 2019-03-28, Balance as of period end |
| 2016-12-31 | $78.52M | -18.6% | 2018-04-02, Balance as of period end |
| 2015-12-31 | $96.51M | -20.3% | 2017-03-31, Balance as of period end |
| 2014-12-31 | $121.08M | -23.2% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $157.61M | -3.4% | 2015-12-28, Balance as of period end |
| 2012-12-31 | $163.24M | +4.4% | 2014-03-20, Balance as of period end |
| 2011-12-31 | $156.39M | +18.7% | 2013-03-14, Balance as of period end |
| 2010-12-31 | $131.75M | n/a | 2012-03-14, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $31.00M | +108.2% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $22.88M | -46.9% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $59.87M | -5.3% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $19.07M | -13.4% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $117.81M | +50.4% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $7.45M | +33.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $8.36M | +21.2% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $353.77M | -26.6% |
Compare CPHI, CRVO, PRPH, MRKR side by side · Screen every company in Pharmaceutical Preparations ↗